

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

Row Num	Generic Name	Trade Name	Designation Date	Orphan Designation	Contact Company/Sponsor
1	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
2	Filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
3	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
4	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

5	5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Novartis Pharmaceuticals Corporation
6	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
7	MEK162 + LGX818	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Novartis Pharmaceuticalues Corporation
8	Methyl [(2S)-1-[[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl)-1-isopropyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino}-2-propanyl]carbamate	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma postive for BRAF mutation	Novartis Pharmaceuticals Corporation
9	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
10	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
11	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
12	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol	n/a	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
13	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	GlaxoSmithKline LLC
14	Poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics, Inc

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

15	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
16	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
17	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolix, Inc.
18	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
19	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
20	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC
21	isavuconazonium sulfate	n/a	10/25/2013	Treatment of zygomycosis	Astellas
22	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
23	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
24	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

25	trastuzumab emtansine	Kadcyla Kadcyla®	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genethech, Inc.
26	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BIOBLAST PHARMA LTD.
27	Gallium-68 (DOTA0-Phe1-Tyr3)octreotide	n/a	10/23/2013	The management of neuroendocrine tumors	Society of Nuclear Medicine & Molecular Imaging
28	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
29	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
30	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
31	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
32	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Stem Cell Therapeutics Corporation
33	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
34	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
35	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
36	olaparib	n/a	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
37	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

38	6-amino-5-chloro-N-[1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
39	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporation
40	ibrutinib	n/a	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
41	idelalisib	n/a	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc
42	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
43	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
44	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
45	LDK378	n/a	9/27/2013	Treatment of non-small cell lung cancer that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
46	self-complimentary adeno-associated virus vector, serotype 9, packaging the full length GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
47	1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one	n/a	9/26/2013	Management of postherpetic neuralgia	Zalicus Pharmaceuticals Ltd.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

48	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
49	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	GT Biologics Ltd
50	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	GANYMED Pharmaceuticals AG
51	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
52	ethiodized oil injection	n/a	9/26/2013	Diagnostic for the management of patients with hepatocellular carcinoma	Guerbet LLC
53	idelalisib	n/a	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
54	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Waldenstrom's macroglobulinemia	Gilead Sciences, Inc.
55	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where gadolinium based contrast agents are contraindicated or cannot be administered	CMC Contrast AB
56	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
57	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

58	anti-sense oligonucleotide consisting of 2'âO-Me RNA with a phosphorothioate backbone	n/a	9/23/2013	Treatment of cystic fibrosis	ProQR therapeutics B.V.
59	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
60	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
61	lenalidomide	Revlimid	9/13/2013	Treatment of follicular lymphoma	Celgene Corporation
62	4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
63	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
64	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
65	autologous ex vivo expanded CD4+ enriched leukocytes treated with the de-methylating agent 5-aza-2'âO-methyl-2-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
66	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	SeattleGenetics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

67	aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Ctr for Cellular & Molecular Therapeutics
68	human monoclonal IgG2 to human proprotein convertase subtilisin/kexin type 9	n/a	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
69	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia of malignancy	Amgen, Inc.
70	human glial restricted progenitor cells and their progeny	Q-Cells(R)	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
71	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
72	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
73	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
74	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi
75	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
76	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.
77	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
78	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

79	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
80	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
81	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
82	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Lumena Pharmaceuticals, Inc.
83	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Lumena Pharmaceuticals' Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

84	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Lumena Pharmaceuticals, Inc.
85	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Lumena Pharmaceuticals, Inc.
86	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
87	fenretinide	n/a	9/4/2013	Treatment of peripheal T-cell lymphoma	CerRx, Inc.
88	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
89	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

90	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
91	pomalidomide	n/a	8/22/2013	Treatment of systemic sclerosis	Celgene Corporation
92	dantrolene sodium suspension for injection	n/a	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
93	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
94	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
95	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
96	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
97	pentamidine	n/a	8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Oncozyme Pharma, Inc.
98	pentamidine	n/a	8/12/2013	Treatment of ovarian cancer	Oncozyme Pharma, Inc.
99	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
100	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
101	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

102	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
103	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
104	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
105	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
106	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
107	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
108	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
109	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
110	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

111	hydroxycarbamide (hydroxyurea)	Siklos(R)	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
112	(5R)-5-(4-([2-fluorophenyl)methyl]oxy)phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.
113	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics Ltd
114	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients who are unable to take oral topiramate	Ligand Pharmaceuticals, Inc.
115	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
116	N-methyl-4-({4-([3-methyl(methylsulfonyl)amino]pyrazin-2-yl)methyl)amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
117	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
118	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	LaJolla Pharmaceutical company, Inc.
119	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
120	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

121	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
122	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
123	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylis Pharma AS
124	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck, LLC
125	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
126	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
127	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center
128	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
129	cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
130	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

131	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation	Pharmalink AB
132	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
133	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
134	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
135	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
136	abatacept	Orencia	5/30/2013	Treatment of type I diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
137	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
138	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacylics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

139	modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Bayer HealthCare Pharmaceuticals, Inc.
140	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
141	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.
142	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
143	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
144	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
145	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
146	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alya-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
147	N-{3-[(2-[[4-(4-acetyl)piperazin-1-yl]-2-methoxyphenyl]amino)-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl}prop-2-enamide	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
148	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
149	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

150	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
151	isavuconazonium sulfate	n/a	5/6/2013	Treatment of invasive aspergillosis.	Astellas
152	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Glaxo Wellcome Mfg Pte Ltd
153	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	Jennerex, Inc.
154	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
155	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
156	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
157	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
158	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD
159	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

160	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
161	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
162	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
163	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	Shape Pharmaceuticals, Inc.
164	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Synageva BioPharma Corp.
165	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
166	sodium ascorbate and menadione sodium bisulfite	n/a	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
167	daunorubicin citrate liposome	Daunoxome	4/15/2013	Treatment of acute myeloid leukemia	Galen Limited
168	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
169	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

170	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
171	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
172	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
173	anti-inhibitor coagulant complex	Feiba Nf	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxter Healthcare Corporation
174	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
175	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
176	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
177	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
178	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

179	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
180	recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
181	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
182	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed Incorporated
183	N-tert-butyl-3-[(5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
184	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease).	Novo Nordisk, Inc.
185	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

186	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
187	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
188	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
189	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Acceleron Pharma, Inc
190	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
191	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
192	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
193	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.
194	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, LLC
195	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
196	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Acceleron Pharma, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

197	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
198	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
199	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.
200	recombinant human Naglu- insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
201	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
202	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
203	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann-Pick disease type C	National Institutes of Health
204	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
205	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
206	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
207	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

208	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
209	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
210	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Prosensa Therapeutics B V
211	Exon 52 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Prosensa Therapeutics B V
212	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Prosensa Therapeutics B.V.
213	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Prosensa Therapeutics B.V.
214	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
215	onartuzumab	n/a	1/23/2013	Treatment of gastric cancer including gastroesophageal cancer	Genentech, Inc.
216	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

217	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
218	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinoxa Pharma
219	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
220	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	N-Gen Research Laboratories, Inc.
221	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
222	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/15/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH
223	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
224	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
225	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
226	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
227	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
228	riloncept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
229	paclitaxel nanoparticles	n/a	1/3/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

230	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe pre-eclampsia	Salupont Consulting Ltd
231	elafin	n/a	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
232	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of refractory ascites due to all etiologies except for cancer	PharmaIN Corporation
233	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
234	lenvatinib	n/a	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
235	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
236	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
237	methylene blue0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

238	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
239	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
240	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
241	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
242	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
243	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
244	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	S. Cotter
245	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
246	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

247	recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen	n/a	12/3/2012	Treatment of pancreatic cancer	Astellas Pharma Global Development, Inc.
248	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
249	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma.	Pharmacyclics, Inc.
250	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
251	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
252	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
253	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
254	1'-[[5-(trifluoromethyl)-2-furyl]methyl]spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
255	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
256	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

257	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OXiGene, Inc.
258	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
259	humanized anti programmed cell death 1 monoclonal IgG4 antibody	n/a	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
260	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
261	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
262	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
263	tabalumab	n/a	11/19/2012	Treatment of multiple myeloma	Eli Lilly and Company
264	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
265	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
266	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
267	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
268	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

269	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxter Healthcare Corporation
270	sirolimus	Rapamune(R)	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
271	(2S)-2-(((2R)-2-([3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino}butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestasis	Albireo AB
272	(2S)-2-(((2R)-2-([3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino}butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
273	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
274	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

275	5'-GAATATTAACAICTGACAAGTC-3'	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
276	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
277	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS
278	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
279	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.
280	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH
281	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
282	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
283	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
284	liposomal α -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
285	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
286	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
287	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

288	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
289	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
290	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
291	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	Cell Therapeutics, Inc.
292	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl)-N-({3-nitro-4-[tetrahydro-2H-pyran-4-ylmethyl]amino}phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc.
293	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
294	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
295	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
296	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Nerviano Medical Sciences S.r.l.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

297	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
298	trametinib and dabrafenib	n/a	9/20/2012	Treatment of Stage IIb through IV melanoma.	GlaxoSmithKline
299	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
300	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
301	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC
302	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
303	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
304	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC
305	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	Pharma Mar USA Inc.
306	mercaptopurine	n/a	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

307	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
308	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Aerial BioPharma, LLC
309	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
310	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
311	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
312	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
313	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
314	Brilliant Blue G	Dorc Ilm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
315	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
316	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

317	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
318	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
319	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
320	acetyl-L-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
321	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
322	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
323	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
324	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collagenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

325	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
326	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
327	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
328	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
329	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
330	tralokinumab (recombinant human and anti-interleukin-13 monoclonal antibody)	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
331	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
332	mecasermin rinfabate	lplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
333	everolimus	Afinitor(R)	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
334	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
335	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteiny-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteiny-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use in combination with G-CSF to mobilize HSCs from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	Biokine Therapeutics Ltd.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

336	benzoate	n/a	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
337	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
338	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
339	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
340	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
341	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
342	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	EcoPharm Corporation
343	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
344	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
345	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
346	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC
347	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

348	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
349	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
350	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic (NYHA class III or IV) hypertrophic cardiomyopathy	Heart Metabolics, Ltd.
351	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
352	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
353	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Lonza
354	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
355	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	6/1/2012	Prevention of acute radiation toxicity, also known as Acute Radiation Syndrome (ARS)	Onconova Therapeutics, Inc.
356	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
357	golimumab	Simponi Aria	5/21/2012	Treatment of sarcoidosis	Janssen Biotech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

358	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
359	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation
360	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
361	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
362	eribulin mesylate	Halaven(R)	5/14/2012	Treatment of advanced soft tissue sarcoma	Eisai, Inc.
363	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
364	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC
365	eptifibatid and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
366	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
367	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

368	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science, Inc.
369	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
370	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
371	ibrutinib	n/a	4/6/2012	Treatment of chronic lymphocytic leukemia	Pharmacyclics, Inc.
372	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
373	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
374	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
375	golimumab	Simponi Aria	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
376	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1,1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
377	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
378	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
379	ilorasertib	n/a	3/16/2012	Treatment of ovarian cancer	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

380	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
381	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi Pharmaceuticals, Inc.
382	talarazole	n/a	3/16/2012	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
383	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
384	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
385	(N-[2,6-bis(1-methylethyl)-phey-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl] urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.
386	2,2'-(2-[1R)-1-(((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl]diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
387	2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridinium sulfate	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
388	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
389	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

390	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
391	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
392	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
393	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
394	Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor	n/a	2/17/2012	Treatment of glioblastoma multiforme (GBM).	AbbVie, Inc.
395	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Onclave Therapeutics Limited
396	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
397	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
398	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
399	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
400	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
401	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

402	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Rottapharm S.p.A.
403	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
404	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
405	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
406	ramucirumab	n/a	2/16/2012	Treatment of gastric cancer	ImClone Systems LLC
407	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
408	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Glenveigh Medical, LLC
409	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	Del Mar Pharmaceuticals (BC), Ltd.
410	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
411	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
412	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
413	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

414	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
415	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
416	sodium nitrate	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
417	ustekinumab	Stelara	12/28/2011	Treatment of chronic sarcoidosis	Janssen Biotech, Inc.
418	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	INO Therapeutics
419	ustekinumab; human monoclonal antibody to interkeukin 12p40	Stelara	12/22/2011	Treatment of primary biliary cirrhosis	Janssen Biotech, Inc.
420	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
421	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
422	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

423	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
424	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD
425	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
426	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
427	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
428	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
429	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
430	profimer sodium	Photofrin	12/2/2011	Treatment of malignant mesothelioma	Pinnacle Biologics, Inc.
431	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy.	ReveraGen Biopharma

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

432	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Marathon Pharmaceuticals, LLC
433	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
434	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
435	MCMV5322A/MCMV3068A	n/a	11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Genentech
436	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
437	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

438	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
439	Ramucirumab; rHuman MAb to VEGFR-2	n/a	11/4/2011	Treatment of hepatocellular carcinoma.	ImClone Systems LLC
440	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
441	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

442	heparin activated recombinant human fibroblast growth factor 1 (FGF1) in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury (Scale A)	BioArctic Neuroscience AB
443	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
444	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
445	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
446	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Therapeutics, LLC
447	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
448	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
449	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
450	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

451	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Archer Biosciences
452	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
453	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
454	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
455	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
456	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
457	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
458	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
459	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
460	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
461	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
462	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
463	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

464	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.
465	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
466	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure.	Digna Biotech S.L.
467	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.
468	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
469	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
470	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

471	1-(3-chloro-5-[[4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
472	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
473	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
474	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
475	5-Fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Gilead Sciences, Inc.
476	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
477	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
478	lanreotide acetate	n/a	8/25/2011	Treatment of neuroendocrine tumors.	Ipsen Biopharmaceuticals, Inc.
479	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
480	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
481	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases
482	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

483	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
484	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
485	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
486	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
487	1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)	n/a	7/28/2011	Treatment of acute myelogenous leukemia	AbbVie, Inc.
488	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.
489	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
490	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
491	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
492	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Phytopharm plc
493	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

494	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
495	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
496	low molecular weight dextran sulfate	lbsolvmir(R)	7/6/2011	Treatment to mobilize progenitor cells prior to stem cell transplantation	TikoMed AB
497	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
498	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
499	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	ExSAR Corporation
500	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
501	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
502	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
503	nintedanib	n/a	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim
504	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
505	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

506	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
507	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc
508	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
509	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
510	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Targovax AS
511	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
512	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	ViroPharma, Inc.
513	recombinant human minibody against complement component	n/a	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.r.l

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

514	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
515	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
516	Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	6/1/2011	Treatment of myelofibrosis.	Gilead Sciences, Inc.
517	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
518	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
519	exendin-(9-39)	n/a	6/1/2011	Treatment of congenital hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children.	The Children's Hospital of Philadelphia
520	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
521	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
522	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutliple myeloma	XTL Biopharmaceuticals, Ltd
523	everolimus	Afinitor	5/24/2011	Treatment of gastric cancer	Novartis Pharmaceuticals Corporation
524	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	Stason Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

525	recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	5/17/2011	Treatment of pancreatic cancer.	Gilead Sciences, Inc.
526	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
527	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
528	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
529	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
530	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	EndoChem, Inc.
531	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory
532	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
533	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
534	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
535	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
536	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

537	bortezomib	Velcade For Injection	4/18/2011	Treatment of mantle cell lymphoma (MCL).	Millennium Pharmaceuticals, Inc.
538	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
539	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
540	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corp.
541	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
542	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Asparaginyl]-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated wth solid organ transplantation	Endotis Pharma
543	Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/2011	Treatment of idiopathic pulmonary fibrosis	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

544	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amlie-Lefond, MD
545	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Archer Biosciences
546	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
547	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
548	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.
549	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	mondoBIOTECH Laboratories AG
550	perillyl alcohol	n/a	4/18/2011	Treatment of glioma.	NeOnc Technologies, Inc.
551	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies
552	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
553	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
554	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

555	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronema Syndrome	Novartis Pharmaceuticals Corporation
556	brivanib alaninate	n/a	3/21/2011	Treatment of hepatocellular carcinoma	Bristol-Myers Squibb
557	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
558	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
559	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
560	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
561	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
562	acetyl-l-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	sigma-tau Pharmaceuticals, Inc.
563	rigisertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
564	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A. de C.V.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

565	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
566	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondzione Telethon
567	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
568	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
569	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
570	herpes simplex Type-1 virus encoded with human granulocyte-	Oncovexgm-Csf	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc.
571	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
572	crenolanib	n/a	3/11/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
573	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
574	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
575	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
576	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

577	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
578	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
579	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
580	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
581	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminy-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylamide disulfide	n/a	2/18/2011	Treatment of pancreatic cancer.	Genus Oncology, LLC
582	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
583	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
584	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
585	murine monoclonal antibody against CD26	Begecina	2/18/2011	Treatment of graft versus host disease	Adienne S.r.l.
586	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
587	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light)	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

588	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
589	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
590	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
591	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
592	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
593	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
594	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis.	Neuralstem, Inc.
595	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
596	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
597	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
598	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	mondoBIOTECH Laboratories, AG
599	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

600	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
601	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Theraclone Sciences
602	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Aptalis Pharma US, Inc.
603	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
604	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	GlaxoSmithKline, LLC
605	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
606	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
607	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
608	[AC3-γCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
609	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

610	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
611	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
612	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
613	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
614	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
615	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
616	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
617	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
618	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
619	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.
620	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
621	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
622	chimeric monoclonal antibody 14.18 (ch14.18)	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

623	crenolanib	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
624	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC
625	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
626	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	GlaxoSmithKline, LLC
627	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
628	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
629	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
630	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2.	Fera Pharmaceuticals
631	cediranib	n/a	12/13/2010	Treatment of glioblastoma	AstraZeneca
632	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
633	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
634	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
635	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

636	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
637	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
638	16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
639	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of mechlorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
640	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

641	(Z)-9-[[2,2-bis-(hydroxymethyl)cyclopropylidene]methyl]guanine, cyclopropavir, ZSM-1-62 and NSC D745998	n/a	11/29/2010	Treatment of active cytomegalovirus infections.	Microbiotix, Inc.
642	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	11/29/2010	Treatment of multiple myeloma.	ImmunoGen, Inc.
643	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
644	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
645	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
646	anti-insulin-like type 1 receptor immunoglobulin 1	n/a	11/23/2010	Treatment of pancreatic cancer.	Amgen
647	cyclosporine	n/a	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
648	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
649	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

650	recombinant human coagulation factor VIII Fc fusion protein	n/a	11/23/2010	Treatment of hemophilia A	Biogen Idec Hemophilia, Inc.
651	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
652	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxter Healthcare Corporation
653	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma.	Genentech, Inc.
654	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
655	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
656	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
657	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
658	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Kakko Kirin Pharma, Inc.
659	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
660	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
661	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
662	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
663	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKTor Pharmaceuticals, LLC
664	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

665	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
666	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
667	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
668	fresolimumab	n/a	10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Genzyme
669	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
670	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
671	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
672	(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminoxy)propionyl]-1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
673	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency.	PROLOR-Biotech, Ltd.
674	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

675	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	World Health Organization (WHO)
676	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
677	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
678	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation
679	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	Sucampo Pharma Americas, LLC
680	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
681	acyclovir	n/a	9/16/2010	Treatment of herpetic keratitis	GlaxoSmithKline
682	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
683	everolimus	Afinitor	9/16/2010	Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma)	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

684	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceutical Partners
685	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
686	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
687	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
688	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
689	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
690	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Ziopharm Oncology, Inc.
691	pentamidine	n/a	9/13/2010	Treatment of pancreatic cancer.	Oncozyme Pharma, Inc.
692	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

693	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.
694	Epitalon	n/a	9/2/2010	Treatment of retinitis pigmentosa	BioDiem Ltd
695	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
696	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
697	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
698	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC
699	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
700	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
701	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
702	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
703	Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901	n/a	8/17/2010	Treatment of small cell lung cancer.	ImmunoGen, Inc.
704	14-amino acid peptide derived from wound growth factor	n/a	8/16/2010	Treatment of delayed graft function in renal transplant recipients	NephRx Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

705	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Accelaron Pharma, Inc.
706	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
707	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
708	mycobacterium vaccae	n/a	8/6/2010	Treatment of pancreatic cancer	Immodulon Therapeutics Ltd.
709	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
710	ublrituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
711	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
712	14-amino acid peptide derived from wound growth factor	n/a	8/5/2010	Prevention of delayed graft function in renal transplant recipients	NephRx Corporation
713	N-(cyanomethyl)-4-(2-([4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
714	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Stromedix, Inc.
715	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Trypanosomiasis) caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
716	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

717	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
718	human lysosomal acid lipase, recombinant, transgenic gallus	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Synageva BioPharma Corp.
719	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
720	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
721	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
722	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
723	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia)in hematopoietic stem cell transplants.	US Biotest, Inc.
724	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
725	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
726	bosentan	Tracleer(R)	6/7/2010	Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis	Actelion Ltd.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

727	anti-TCR murine monoclonal antibody (MAb, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.
728	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2, TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
729	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
730	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
731	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
732	refanalin	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
733	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Childrens Hospital & Research Center Oakland
734	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
735	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
736	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

737	Lentiviral vector containing the human MY07A gene (UshStat)	n/a	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Oxford BioMedica (UK) Ltd.
738	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
739	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
740	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Oxford Biomedica (UK) Ltd.
741	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
742	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
743	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases
744	Glyceraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
745	ex-vivo cultured adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Osiris Therapeutic, Inc.
746	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
747	2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide	n/a	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

748	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
749	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
750	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	Fondazione Telethon
751	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
752	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
753	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
754	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
755	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
756	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

757	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
758	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
759	(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-	(3s)-3-{4-[7-(Aminocarbonyl)-2	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
760	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
761	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure	Ocera Therapeutics, Inc.
762	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	New Zealand Pharmaceuticals Ltd
763	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
764	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
765	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
766	secukinumab	n/a	3/26/2010	Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression	Novartis Pharmaceutical Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

767	ruxolitinib phosphate	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
768	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Fresenius Biotech North America
769	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
770	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
771	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
772	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
773	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
774	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Manchester Pharmaceuticals, Inc.
775	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
776	Fast skeletal muscle troponin activator	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
777	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
778	maytansinoid DM1-conjugated humanized monoclonal antibody N901	n/a	3/2/2010	Treatment of Merkel cell carcinoma	ImmunoGen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

779	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
780	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
781	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
782	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
783	allogeneic hematopoietic stem cell	Atir(Tm)	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
784	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with chronic myeloid leukemia	Gamida Cell - Teva Joint Venture
785	allogeneic ex vivo expanded umbilical cord blood cells	Stemex	2/1/2010	For use as hematopoietic support in patients with myelodysplastic syndromes	Gamida Cell - Teva Joint Venture
786	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

787	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico
788	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
789	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
790	N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
791	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
792	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
793	2-[[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
794	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

795	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
796	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
797	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
798	tasimelteon	n/a	1/19/2010	Treatment of non-24 hour sleep/wake disorder in blind individuals without light perception.	Vanda Pharmaceuticals, Inc.
799	amitriptyline and ketamine	Epicept(TM) Np-1	1/19/2010	Treatment of postherpetic neuralgia	EpiCept Corporation
800	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
801	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
802	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
803	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
804	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
805	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Kyowa Hakko Kirin Pharma, Inc. (KKP)

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

806	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
807	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
808	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
809	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
810	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.
811	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
812	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
813	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
814	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
815	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
816	late stage human motor neuron progenitors	Motorgraft(TM)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
817	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
818	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

819	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
820	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
821	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
822	3,4-Diaminopyridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceutical Partners, Inc.
823	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44 of the dystrophin gene.	Prosensa Therapeutics B.V.
824	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD).	Alexion Pharmaceuticals, Inc.
825	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
826	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexia, Inc.
827	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease.	Lithera, Inc.
828	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

829	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
830	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
831	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
832	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
833	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
834	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	GlaxoSmithKline
835	S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDESNISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
836	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
837	low molecular weight dextran sulfate	lbsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
838	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

839	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
840	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
841	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
842	Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/2009	Treatment of stage IIb to IV melanoma	Abraxis BioScience, LLC
843	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
844	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
845	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
846	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
847	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

848	cethromycin	Restanza(TM)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
849	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
850	2-[(R)-2methylpyrrolidin-2-yl]-1h-benzimidazole-4-carbozamide	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
851	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC
852	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
853	Belinostat	n/a	9/3/2009	Treatment of peripheral T-cell lymphoma	Spectrum Pharmaceuticals, Inc.
854	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
855	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
856	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

857	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
858	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
859	perifosine	n/a	9/3/2009	Treatment of multiple myeloma.	Aeterna Zentaris GmbH
860	progesterone	n/a	9/3/2009	For early intervention in the treatment of moderate to severe closed-head traumatic brain injury	BHR Pharma, LLC
861	rigisertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
862	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
863	uridine triacetate	n/a	9/3/2009	Treatment of mitochondrial disease	Wellstat Therapeutics Corporation
864	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

865	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
866	autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
867	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
868	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	GlaxoSmithKline
869	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
870	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Tau Therapeutics, LLC
871	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
872	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
873	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmmed, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

874	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
875	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
876	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
877	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Only for Children Pharmaceuticals
878	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
879	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic grafted host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.
880	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
881	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
882	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Antisense Pharma GmbH
883	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
884	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

885	anti-nogo-A monoclonal antibody	n/a	7/7/2009	Treatment of amyotrophic lateral sclerosis	GlaxoSmithKline
886	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Fresenius Biotech North America, Inc.
887	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
888	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
889	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
890	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
891	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
892	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	GlaxoSmithKline

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

893	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	GlaxoSmithKline
894	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	GlaxoSmithKline Biologicals, S.A.
895	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
896	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
897	ranagengliotucel-L	Glionix(TM)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
898	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continuous Renal Replacement Therapy	Baxter Healthcare Corporation
899	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
900	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
901	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

902	N-tert-butyl-3-[5-methyl-2-{{4-(2-pyrrolidin-1-ylethoxy)phenyl}amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
903	aztreonam	n/a	5/15/2009	Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.	Gilead Sciences, Inc.
904	elosulfase alfa	n/a	5/15/2009	Treatment of mucopolysaccharidosis Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical, Inc.
905	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
906	S-nitroglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMaceuticals, LLC
907	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
908	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
909	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

910	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
911	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
912	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil poisoning	Wellstat Therapeutics Corp.
913	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
914	Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent	Kogenate Fs/Liposomal Diluent	4/29/2009	Treatment of hemophilia A	Bayer HealthCare LLC
915	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
916	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Hyperion Therapeutics, Inc.
917	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.
918	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
919	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
920	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
921	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

922	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire Regenerative Medicine, Inc.
923	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
924	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
925	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula maturation and arteriovenous graft failure in patients with end stage renal disease who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
926	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
927	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
928	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

929	N-(5-tert-Butylisoxazol-3-yl)-N'-(4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
930	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
931	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
932	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
933	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.
934	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	GlaxoSmithKline
935	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
936	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Eli Lilly and Company
937	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
938	bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
939	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

940	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech
941	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexylpropanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	GlycoMimetics, Inc.
942	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Trophos SA
943	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.
944	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
945	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
946	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
947	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
948	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.r.l.
949	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.r.l.
950	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

951	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	BioSynthema, Inc.
952	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
953	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
954	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International, Inc
955	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
956	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
957	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	Cell Therapeutics Inc.
958	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
959	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
960	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
961	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
962	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium faliparum	Zydus Pharmaceuticals, Inc.
963	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

964	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	Gilead Sciences, Inc.
965	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
966	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
967	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
968	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
969	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
970	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease, type C.	Actelion Pharmaceuticals Ltd
971	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
972	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
973	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
974	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
975	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
976	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
977	antineoplaston A10, antineoplaston AS2-1	n/a	10/30/2008	Treatment of gliomas	Burzynski Research Institute, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

978	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
979	recombinant human coagulation factor IX fusion protein	n/a	10/30/2008	For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec
980	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
981	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
982	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
983	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
984	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
985	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
986	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
987	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Tau Therapeutics, LLC
988	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

989	Adeno-associated viral vector serotype 5 containing human ABCA4 gene	n/a	9/30/2008	Treatment of Stargardt's disease.	Fondazione Telethon
990	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Novagali Pharma S.A.
991	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
992	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
993	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
994	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
995	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
996	[131I]-N-(2-(diethylamino) ethyl-4-(4 fluorebenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc.
997	eliglustat	n/a	9/17/2008	Treatment of Gaucher disease	Genzyme Corporation
998	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Formac Pharmaceuticals, NV
999	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1000	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharma International

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1001	allogeneic mesenchymal precursor cells derived from ex vivo healthy donors harvested from iliac crest.	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1002	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Fresenius Biotech North America
1003	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
1004	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
1005	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
1006	propranolol	n/a	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
1007	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
1008	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
1009	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1010	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl]-1H-benzimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
1011	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
1012	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
1013	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
1014	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
1015	glycafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
1016	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
1017	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
1018	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
1019	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia.	ApoPharma, Inc.
1020	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1021	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
1022	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
1023	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of toxemia associated with inhalational anthrax.	Cangene Corporation
1024	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1025	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethyl)pyridin-2-yl]-benzotrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
1026	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
1027	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
1028	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1029	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
1030	[Nle4, D-Phe7]-a-melanocyte stimulating hormone	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
1031	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
1032	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Aires Pharmaceuticals, Inc.
1033	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
1034	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
1035	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Center for Cellular & Molecular Therapeutics
1036	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
1037	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
1038	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
1039	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
1040	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited
1041	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1042	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
1043	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
1044	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	DURECT Corporation
1045	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
1046	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1047	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1048	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
1049	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	ViroPharma, Inc.
1050	cenersen	Aeza	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
1051	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
1052	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen Rockville, Inc.
1053	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen Rockville, Inc.
1054	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen Rockville, Inc.
1055	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen Rockville, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1056	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
1057	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
1058	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
1059	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	GlaxoSmithKline
1060	Palifosfamide	n/a	5/5/2008	Treatment of soft tissue sarcomas	ZIOPHARM Oncology, Inc.
1061	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
1062	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
1063	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
1064	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation
1065	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Novagali Pharma S.A.
1066	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
1067	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1068	Anti-von Willebrand Aptamer	n/a	4/9/2008	Treatment of thrombotic thrombocytopenic purpura	Archemix Corporation
1069	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
1070	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
1071	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada, Ltd.
1072	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.
1073	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
1074	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
1075	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients	CSL Behring, LLC
1076	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
1077	pacritinib	n/a	3/13/2008	Treatment of myeloproliferative disorders with the JAK2 V617F mutation	Cell Therapeutics, Inc..
1078	amrubicin	n/a	3/10/2008	Treatment of small cell lung cancer	Celgene Corporation
1079	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
1080	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1081	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition-associated liver disease	Fresenius Kabi Deutschland GmbH
1082	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Mpex Pharmaceuticals, Inc.
1083	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
1084	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
1085	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
1086	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
1087	cenersen	Aeza	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
1088	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
1089	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1090	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
1091	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1092	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
1093	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
1094	paclitaxel aqueous gel	Oncogel(TM)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
1095	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
1096	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	MethylGene
1097	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
1098	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1099	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
1100	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
1101	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
1102	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
1103	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
1104	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
1105	recombinant human rod-derived cone viability factor	n/a	1/7/2008	Treatment of retinitis pigmentosa	Fovea Pharmaceuticals
1106	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1107	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
1108	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
1109	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Cephalon, Inc.
1110	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
1111	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
1112	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
1113	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
1114	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
1115	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
1116	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
1117	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
1118	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1119	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
1120	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmmed, Inc.
1121	rindopepimut	n/a	11/19/2007	Treatment of EGFRVIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.
1122	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
1123	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
1124	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
1125	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
1126	Human factor X	n/a	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
1127	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
1128	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1129	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
1130	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepion Pharmaceuticals, LLC
1131	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Canada, Inc.
1132	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	n/a	10/23/2007	Treatment of acute myelogenous leukemia	AbbVie, Inc.
1133	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1134	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
1135	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
1136	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
1137	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1138	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
1139	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Biogen Idec, Inc.
1140	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
1141	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
1142	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
1143	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1144	parathyroid hormone	n/a	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
1145	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
1146	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
1147	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.
1148	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
1149	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1150	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	MethylGene, Inc.
1151	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
1152	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
1153	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
1154	(R)-2-methyl-6-nitro-2-[4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxy-methyl]-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd
1155	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis.	Global Alliance for TB Drug Development
1156	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
1157	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
1158	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1159	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
1160	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
1161	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
1162	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Tau Therapeutics, LLC
1163	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
1164	N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea	n/a	5/23/2007	Treatment of hepatocellular carcinoma	AbbVie, Inc.
1165	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
1166	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRs).	Applied Genetic Technologies Corporation
1167	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
1168	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1169	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
1170	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	NOVAGALI Pharma SA

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1171	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
1172	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
1173	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
1174	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
1175	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
1176	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.r.l.
1177	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
1178	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1179	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
1180	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteogenic sarcoma metastatic to the lung	Eleison Pharmaceuticals, LLC
1181	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Applied Genetic Technologies Corporation
1182	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	Oncolmmune, Inc.
1183	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
1184	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
1185	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
1186	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharaceuticals Limited
1187	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Sigma-Tau Pharmaceuticals, Inc.
1188	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGpPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG
1189	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
1190	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1191	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	ViroPharma Inc.
1192	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
1193	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
1194	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation
1195	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
1196	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Aastrom Biosciences, Inc.
1197	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
1198	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
1199	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
1200	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1201	droxidopa	n/a	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Chelsea Therapeutics, Inc.
1202	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
1203	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Cinergen, LLC
1204	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
1205	vinCRISTine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
1206	dihydroartemisinin and piperaquine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1207	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1208	Epstein Barr Virus specific cytotoxic T lymphocytes	n/a	12/27/2006	Prevention and treatment of EBV-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.	Center for Cell and Gene Therapy
1209	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
1210	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-[[{(3S)-3-(dimethylamino)pyrrolidin-1-yl)methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
1211	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
1212	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis.	Meritage Pharma, Inc.
1213	Cyclo {{{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.
1214	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1215	Rose Bengal Disodium	n/a	12/20/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
1216	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
1217	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
1218	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
1219	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
1220	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
1221	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
1222	risedronate sodium	Actonel	12/18/2006	Treatment of patients with osteogenesis imperfecta.	Warner Chilcott Pharmaceuticals
1223	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
1224	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
1225	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
1226	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
1227	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
1228	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1229	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
1230	Estradiol Gel	Estrogel (R)	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics, Inc.
1231	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
1232	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
1233	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
1234	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.
1235	Mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Cinergen
1236	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
1237	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Paladin Therapeutics, Inc.
1238	Coagulation Factor VIIa (Recombinant)	Novoseven	10/3/2006	Treatment of bleeding in patients experiencing intracranial hemorrhage.	Novo Nordisk, Inc.
1239	Sorafenib	Nexavar	9/29/2006	Treatment of stage IIB through stage IV melanoma	Bayer Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1240	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Vallinex Incorporated
1241	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
1242	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
1243	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
1244	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
1245	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1246	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
1247	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Repligen Corporation
1248	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
1249	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
1250	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	MAT Biopharma
1251	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
1252	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1253	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	California Stem Cell, Inc.
1254	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1255	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation
1256	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
1257	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1258	Decitabine	Dacogen	8/4/2006	Treatment of acute myeloid leukemia	Eisai, Inc.
1259	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV
1260	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure	Nora Therapeutics, Inc.
1261	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino]acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
1262	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S
1263	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
1264	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Alan L. Buchman, M.D., M.S.P.H.
1265	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1266	pralatrexate	Folotyng	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
1267	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
1268	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
1269	Indium-111 pentetretotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
1270	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
1271	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1272	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1273	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
1274	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Fresenius Biotech North America, Inc.
1275	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
1276	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
1277	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
1278	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
1279	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1280	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
1281	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	AesRx, LLC
1282	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
1283	siltuximab	n/a	5/26/2006	Treatment of Castleman's disease	Janssen Research & Development, LLC
1284	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
1285	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc
1286	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
1287	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
1288	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals, LLC
1289	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation
1290	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXiGENE, Inc.
1291	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1292	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
1293	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
1294	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
1295	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
1296	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
1297	Recombinant coagulation factor VIIa	Novoseven	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
1298	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1299	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
1300	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
1301	Human immune globulin	Xepol(Tm)	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1302	Ethanol gel	n/a	3/29/2006	Treatment of congenital venous malformations	Orfagen
1303	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
1304	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
1305	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
1306	(UDU-stereoisomer of c-UJUun UNU-terminal UkJUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
1307	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
1308	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
1309	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
1310	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
1311	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
1312	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
1313	Ethanol gel	n/a	3/13/2006	Treatment of congenital lymphatic malformations	Orfagen
1314	Human umbilical tissue-derived cells	n/a	3/13/2006	Treatment of retinitis pigmentosa	Janssen Research and Development, LLC
1315	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1316	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
1317	Amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmmed, Inc.
1318	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
1319	Clazosentan	Erajat	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
1320	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
1321	Nikkomyacin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
1322	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
1323	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
1324	Blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen Rockville, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1325	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
1326	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
1327	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
1328	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
1329	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development & Commercializat
1330	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
1331	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
1332	lobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
1333	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Errant Gene Therapeutics, LLC
1334	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
1335	Human immunogloblin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
1336	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1337	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
1338	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
1339	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or teated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
1340	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
1341	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1342	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
1343	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
1344	Ex vivo cultured adult human mesenchymal stem cells	Prochymal	12/14/2005	Treatment of acute graft versus host disease	Osiris Therpeutics, Inc.
1345	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Techologies, Inc

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1346	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
1347	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
1348	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
1349	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
1350	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
1351	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
1352	Exon 46 specific phosphorothioate oligonucleotide	n/a	11/18/2005	Treatment of Duchenne muscular dystrophy	GlaxoSmithKline
1353	Recombinant derivative of C3 transferase	Cethrin(Tm)	11/18/2005	Treatment of acute spinal cord injury.	BioAxone BioSciences, Inc.
1354	Heparin	n/a	11/3/2005	Treatment of cystic fibrosis	Vectura Group, Inc.
1355	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
1356	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
1357	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1358	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
1359	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
1360	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP
1361	iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
1362	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
1363	siltuximab	n/a	10/11/2005	Treatment of multiple myeloma	Janssen Research & Development, LLC
1364	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1365	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
1366	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Avicena Group, Inc.
1367	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1368	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
1369	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
1370	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
1371	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1372	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1373	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
1374	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
1375	Chimeric monoclonal antibodies	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection.	Thallion Pharmaceuticals, Inc.
1376	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1377	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Eli Lilly and Company
1378	tyrosine kinase inhibitor	n/a	9/14/2005	Treatment of mastocytosis	AB Science
1379	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
1380	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
1381	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
1382	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
1383	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation
1384	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
1385	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
1386	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1387	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	ITG Isotope Technologies Garchig GmbH
1388	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
1389	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
1390	Raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
1391	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
1392	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
1393	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
1394	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
1395	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
1396	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1397	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
1398	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
1399	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
1400	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
1401	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
1402	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
1403	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1404	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.
1405	Ibictadekin	n/a	6/3/2005	Treatment of renal cell carcinoma	GlaxoSmithKline LLC
1406	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1407	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Bette S. Pollard, LLC
1408	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
1409	Human anti-integrin receptor av monoclonal antibody	n/a	5/5/2005	Treatment of patients with angiosarcoma	Janssen Research & Development, LLC
1410	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
1411	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
1412	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
1413	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
1414	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
1415	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
1416	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1417	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
1418	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmaceuticals, Inc.
1419	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
1420	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Expression Genetics, Inc.
1421	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
1422	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
1423	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
1424	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
1425	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
1426	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
1427	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1428	Adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie, Inc.
1429	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1430	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
1431	Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood	Stemex	3/4/2005	For use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy	Gamida Cell Ltd - Teva Joint Venture
1432	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLC
1433	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
1434	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
1435	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
1436	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
1437	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
1438	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1439	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a		1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.
1440	Tramadol hydrochloride	n/a		1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
1441	deferoxamine starch conjugate	n/a		1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
1442	recombinant ovine interferon tau	Tauferon		1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
1443	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo		1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
1444	ataluren	n/a		1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene	PTC Therapeutics, Inc.
1445	misoprostol	Gymiso		1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1446	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
1447	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1448	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
1449	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
1450	Riloncept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
1451	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
1452	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
1453	(9-[N-(3-morpholinopropyl)sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
1454	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
1455	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
1456	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
1457	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1458	human anti-integrin receptor avb3/avb5 monoclonal antibody	n/a	12/1/2004	Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma	Janssen Research & Development, LLC
1459	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Pinnacle Biologics, Inc.
1460	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
1461	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
1462	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
1463	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
1464	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
1465	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab,LLC
1466	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
1467	Iaromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
1468	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1469	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
1470	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
1471	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
1472	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma.	Janssen Research & Development, LLC
1473	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/2004	Treatment of neuroblastoma	AbbVie, Inc.
1474	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
1475	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
1476	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
1477	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation
1478	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
1479	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
1480	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1481	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
1482	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
1483	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
1484	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
1485	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
1486	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
1487	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
1488	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
1489	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
1490	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
1491	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1492	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
1493	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
1494	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
1495	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
1496	meclizethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Ceptaris Therapeutics, Inc.
1497	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
1498	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
1499	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
1500	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
1501	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1502	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1503	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
1504	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	GlaxoSmithKline LLC
1505	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
1506	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1507	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
1508	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
1509	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
1510	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
1511	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
1512	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
1513	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
1514	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	ViroPharma Biologics Incorporated
1515	human anti-transforming growth factor-B1,2,3	n/a	7/9/2004	Treatment of idiopathic pulmonary fibrosis	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1516	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
1517	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
1518	Coagulation factor VIIa (Recombinant)	Novoseven	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
1519	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
1520	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
1521	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
1522	Ilirozole	n/a	6/18/2004	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
1523	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
1524	Ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti
1525	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
1526	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1527	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
1528	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
1529	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
1530	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
1531	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
1532	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
1533	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1534	Ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp
1535	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of TISHCON Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1536	pentetate trisodium	Diethylenetriaminepentaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
1537	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
1538	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
1539	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex
1540	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
1541	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
1542	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Adherex Technologies, Inc.
1543	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
1544	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1545	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
1546	Recombinant Porcine Factor VIII, B-domain Deleted	n/a	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxter Healthcare Corporation, Baxter BioScience
1547	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
1548	multi-vitiam infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
1549	5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)	Pirfenidone	3/5/2004	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc.
1550	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
1551	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
1552	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.
1553	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
1554	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1555	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
1556	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's Lymphoma	Mundipharma Research Limited
1557	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
1558	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Biomarin Pharmaceutical Inc.
1559	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
1560	Antivenin crotaline (pit-viper) equine immune F(ab)2	Antivipmyn	1/29/2004	Treatment of envenomation by Crotaline snakes	Instituto Bioclon, S.A de C.V.
1561	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
1562	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmmed, Inc.
1563	N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate	n/a	12/9/2003	Treatment of soft tissue sarcoma	AbbVie, Inc.
1564	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1565	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
1566	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
1567	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological
1568	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of multiple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.
1569	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogeneic lung transplants	APT Pharmaceuticals, Inc.
1570	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
1571	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
1572	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Merck Sante, s.a.a.
1573	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
1574	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1575	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.
1576	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
1577	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1578	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
1579	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
1580	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	11/6/2003	For the prophylaxis of bleeding associated with congenital FXIII deficiency	Novo Nordisk, Inc.
1581	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
1582	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
1583	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato]manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
1584	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
1585	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
1586	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1587	5,5',5''-[Phosphinothiolydine-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
1588	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
1589	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
1590	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1591	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
1592	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbonyl)carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
1593	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
1594	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
1595	2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.
1596	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
1597	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
1598	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc
1599	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1600	cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanic acid)	Falkochol	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Asklepiion Pharmaceuticals LLC
1601	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
1602	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
1603	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
1604	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
1605	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
1606	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
1607	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1608	diphenylcyclophenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
1609	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
1610	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
1611	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
1612	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA
1613	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
1614	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
1615	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	NIH/NIDCR
1616	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
1617	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc.
1618	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1619	DHA-paclitaxel	Taxoprexin	5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Luitpold Pharmaceuticals, Inc.
1620	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
1621	Tretinoin	Atra-iv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
1622	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
1623	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc.
1624	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
1625	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1626	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
1627	polyinosinic-polycytidilic acid	Poly-Icfc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1628	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
1629	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp
1630	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.
1631	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
1632	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
1633	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
1634	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
1635	alteplase	Activase	1/27/2003	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD
1636	a-Galactosidase A	Plant-Produced Human A-Glactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
1637	Mafosfamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
1638	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatic Crohn's disease	Alimentary Health Limited

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1639	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
1640	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
1641	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
1642	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
1643	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
1644	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
1645	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
1646	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
1647	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
1648	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
1649	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1650	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
1651	cobiprostone	n/a	11/14/2002	Treatment of cystic fibrosis	Sucampo Pharma Americas, LLC.
1652	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
1653	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1654	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
1655	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	NeurogesX, Inc.
1656	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
1657	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1658	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
1659	DHA-paclitaxel	Taxoprexin	10/10/2002	Treatment of metastatic malignant melanoma	Luitpold Pharmaceuticals, Inc.
1660	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1661	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1662	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
1663	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.
1664	decitabine	n/a	9/9/2002	Treatment of sickle cell anemia	Eisai, Inc.
1665	polyinosinic-polycytidilic acid	Poly-IcIc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
1666	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer.	Cancer Advances, Inc.
1667	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
1668	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
1669	recombinant human porphobilinogen deaminase, erythropoetic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	ZymenexA/S
1670	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1671	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
1672	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Antisense Pharma GmbH
1673	mecasermin rinfabate	lplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmmed, Inc.
1674	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
1675	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	MediGene, Inc.
1676	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
1677	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
1678	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
1679	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
1680	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
1681	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
1682	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
1683	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1684	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
1685	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
1686	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
1687	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
1688	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
1689	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
1690	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
1691	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
1692	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.
1693	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1694	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
1695	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
1696	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
1697	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
1698	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
1699	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
1700	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
1701	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
1702	tri-antennary glycotriptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1703	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
1704	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
1705	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
1706	IL13-PE38QQR	n/a	11/2/2001	Treatment of malignant glioma	Insys Therapeutics, Inc.
1707	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	PrimeCyte, Inc.
1708	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
1709	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
1710	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
1711	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
1712	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
1713	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1714	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
1715	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
1716	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	PrimeCyte, Inc.
1717	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
1718	DHA-paclitaxel	Taxoprexin	9/25/2001	Treatment of pancreatic cancer	Luitpold Pharmaceuticals, Inc..
1719	ogluferanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
1720	lenalidomide	Revlimid	9/20/2001	Treatment for multiple myeloma	Celgene Corporation
1721	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC
1722	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta Inc.
1723	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc,
1724	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1725	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
1726	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
1727	metreleptin	n/a	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Amylin Pharmaceuticals LLC
1728	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amylin Pharmaceuticals LLC
1729	Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
1730	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
1731	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
1732	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
1733	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
1734	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1735	Intraoral fluoride releasing system	Ifrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
1736	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd
1737	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Abbott
1738	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
1739	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
1740	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
1741	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
1742	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
1743	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA
1744	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
1745	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1746	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
1747	Perflubron	Liquivent	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp.
1748	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
1749	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
1750	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
1751	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
1752	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
1753	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
1754	docosahexanoic acid-paclitaxel	Taxoprexin	3/5/2001	Treatment of hormone-refractory prostate cancer.	Luitpold Pharmaceuticals, Inc.
1755	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
1756	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1757	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc.
1758	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
1759	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
1760	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1761	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Savient Pharmaceuticals, Inc.
1762	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
1763	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
1764	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
1765	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
1766	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
1767	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1768	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
1769	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
1770	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
1771	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
1772	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Ark Therapeutics Ltd.
1773	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
1774	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
1775	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
1776	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
1777	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1778	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
1779	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
1780	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
1781	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
1782	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
1783	Calfactant	Infasurf	9/5/2000	Acute respiratory distress syndrome (ARDS)	ONY, Inc.
1784	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
1785	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.
1786	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
1787	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1788	acid sphingomyelinase	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
1789	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
1790	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
1791	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
1792	Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	7/24/2000	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
1793	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
1794	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
1795	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
1796	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
1797	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
1798	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
1799	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1800	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
1801	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
1802	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
1803	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
1804	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
1805	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
1806	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
1807	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
1808	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals
1809	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1810	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
1811	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1812	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1813	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
1814	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
1815	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
1816	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1817	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab') ₂ bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
1818	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
1819	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
1820	Technetium Tc 99m pterotetramide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1821	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
1822	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	HyBiopharma, Inc.
1823	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
1824	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
1825	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
1826	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1827	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
1828	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
1829	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
1830	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc.
1831	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation
1832	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
1833	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
1834	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
1835	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
1836	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.
1837	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories
1838	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Prevention of mortality in severely burned patients.	Sinclair Pharmaceuticals Ltd

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

1839	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
1840	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1841	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
1842	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd
1843	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
1844	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc.
1845	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
1846	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1847	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
1848	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
1849	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
1850	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline LLC
1851	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
1852	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
1853	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1854	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.
1855	irofulven	n/a	7/27/1999	Treatment of renal cell carcinoma.	Eisai, Inc.
1856	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
1857	irofulven	n/a	7/6/1999	Treatment of ovarian cancer.	Eisai, Inc.
1858	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1859	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
1860	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
1861	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
1862	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1863	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
1864	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1865	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1866	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1867	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1868	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
1869	¹¹¹ Indium pentetretotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
1870	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
1871	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
1872	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
1873	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
1874	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
1875	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
1876	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
1877	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1878	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
1879	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
1880	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1881	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
1882	6-hydroxymethylacylfulvene	n/a	4/6/1999	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	Eisai, Inc.
1883	Eprodisate	Kiacta(TM)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
1884	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
1885	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
1886	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
1887	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
1888	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
1889	Decitabine	n/a	3/8/1999	Treatment of chronic myelogenous leukemia.	Eisai, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1890	Decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Eisai, Inc.
1891	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
1892	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V.
1893	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
1894	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
1895	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	¹³¹ Ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
1896	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
1897	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
1898	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1899	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC
1900	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1901	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
1902	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
1903	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1904	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
1905	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
1906	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Medimmune LLC
1907	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
1908	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1909	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
1910	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1911	Methoxsalen	Uvadex(R)	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.
1912	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
1913	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1914	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
1915	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
1916	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
1917	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
1918	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
1919	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1920	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
1921	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
1922	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
1923	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1924	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
1925	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
1926	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
1927	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Clarassance, Inc.
1928	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1929	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
1930	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1931	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala -glycerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.
1932	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala -glycerolidpalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
1933	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1934	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
1935	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
1936	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
1937	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
1938	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
1939	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
1940	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1941	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1942	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
1943	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
1944	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
1945	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
1946	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
1947	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1948	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
1949	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
1950	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
1951	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
1952	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
1953	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
1954	Recombinant humanized monclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1955	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
1956	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
1957	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
1958	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
1959	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
1960	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
1961	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
1962	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
1963	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
1964	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
1965	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
1966	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1967	Pegylated recombinant human megakaryocyte growth and development factor	Megagen	10/20/1997	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc.
1968	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
1969	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
1970	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
1971	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
1972	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1973	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
1974	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
1975	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1976	Recombinant human acid alpha-glucosidase	1. Myozyme 2.Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
1977	Recombinant human acid alpha-glucosidase	1. Myozyme 2.Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
1978	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
1979	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
1980	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1981	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
1982	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
1983	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
1984	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1985	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
1986	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
1987	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
1988	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
1989	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
1990	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravasion of cytotoxic drugs.	Cancer Technologies, Inc.
1991	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
1992	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
1993	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
1994	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
1995	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
1996	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

1997	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1998	Patul-end	n/a	2/18/1997	Treatment of patulous eustachian tube.	Ear Foundation
1999	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
2000	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
2001	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
2002	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
2003	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
2004	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
2005	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
2006	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2007	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
2008	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
2009	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
2010	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
2011	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
2012	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
2013	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
2014	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
2015	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2016	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
2017	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
2018	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
2019	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.
2020	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2021	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Vidara Therapeutics Research Limited
2022	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
2023	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
2024	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
2025	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
2026	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2027	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
2028	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
2029	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
2030	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
2031	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
2032	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
2033	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
2034	Lipid/DNA human cystic fibrosis gene	n/a	4/8/1996	Treatment of cystic fibrosis.	Genzyme Corporation
2035	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
2036	collagenase clostridium histolyticum	Xiaflex(R)	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
2037	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2038	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
2039	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
2040	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
2041	Antihemophilic factor (recombinant)	Refacto	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
2042	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
2043	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2044	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals
2045	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
2046	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.
2047	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
2048	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Vidara Therapeutics Research Limited
2049	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
2050	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
2051	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
2052	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
2053	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2054	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
2055	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
2056	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
2057	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
2058	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.
2059	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
2060	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
2061	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
2062	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
2063	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2064	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.
2065	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
2066	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
2067	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, INc.
2068	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
2069	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
2070	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
2071	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
2072	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2073	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
2074	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
2075	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
2076	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)
2077	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
2078	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
2079	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
2080	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
2081	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
2082	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
2083	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2084	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
2085	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
2086	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
2087	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
2088	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
2089	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
2090	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
2091	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
2092	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2093	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedita Pharmaceuticals A.G. (Schweiz)
2094	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2095	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
2096	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
2097	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
2098	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
2099	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2100	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2101	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
2102	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2103	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
2104	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
2105	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
2106	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
2107	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
2108	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.
2109	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
2110	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
2111	Ricin (blocked) conjugated murine monoclonal antibody (CD6)	n/a	9/6/1994	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2112	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
2113	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
2114	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
2115	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
2116	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
2117	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
2118	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
2119	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
2120	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
2121	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2122	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2123	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
2124	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
2125	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
2126	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
2127	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
2128	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
2129	8-methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc.
2130	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
2131	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
2132	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2133	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
2134	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
2135	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
2136	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
2137	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
2138	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2139	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
2140	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Alan L. Buchman, MD, MSPH
2141	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
2142	Ammonium tetrathiomolybdate	Coprexa	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
2143	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
2144	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
2145	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2146	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
2147	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
2148	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
2149	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
2150	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
2151	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
2152	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
2153	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and argininosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2154	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
2155	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
2156	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
2157	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2158	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
2159	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
2160	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
2161	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
2162	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
2163	2-O-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
2164	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
2165	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
2166	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
2167	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2168	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
2169	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
2170	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
2171	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
2172	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
2173	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
2174	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
2175	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
2176	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
2177	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2178	RII retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
2179	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
2180	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
2181	Cladribine	Leustatin Injection	4/19/1993	Treatment of non-Hodgkin's lymphoma.	Janssen Research & Development, LLC
2182	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2183	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
2184	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
2185	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.
2186	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
2187	Tretinoin	Atra-lv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2188	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
2189	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
2190	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
2191	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm ³ .	EMD Serono, Inc.
2192	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm ³ .	EMD Serono, Inc.
2193	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.
2194	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
2195	PEG-gluco-cerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in gluco-cerebrosidase.	National Institute of Mental Health, NIH

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2196	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm ³ .	EMD Serono, Inc.
2197	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC
2198	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
2199	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
2200	C1-esterase-inhibitor, human, pasteurized	Berinert P	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
2201	Interleukin-1 receptor antagonist, human recombinant	Anril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Amgen, Inc.
2202	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
2203	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
2204	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2205	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
2206	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
2207	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
2208	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2209	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
2210	Protein C concentrate	Ceprotrin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation
2211	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2212	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
2213	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
2214	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
2215	Sodium Monomercaptoundecahydro-closododecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
2216	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
2217	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2218	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
2219	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
2220	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
2221	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
2222	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
2223	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2224	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
2225	Aminosalicilyc acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company
2226	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
2227	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
2228	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
2229	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
2230	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
2231	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
2232	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
2233	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2234	L-baclofen	Neuralgon	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
2235	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc.
2236	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
2237	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
2238	Botulinum toxin type F	n/a	12/5/1991	Treatment of essential blepharospasm.	Ipsen Limited (name changed from Porton International Inc)
2239	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
2240	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
2241	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
2242	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
2243	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
2244	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2245	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
2246	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
2247	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
2248	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
2249	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
2250	Interleukin-1 receptor antagonist, human recombinant	Anril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Amgen, Inc.
2251	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
2252	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
2253	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2254	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
2255	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
2256	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc.
2257	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc.
2258	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2259	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
2260	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
2261	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
2262	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
2263	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
2264	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
2265	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
2266	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
2267	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
2268	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyrinuria, and variegate porphyria.	Anderson, Karl E., M.D.
2269	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
2270	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2271	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
2272	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
2273	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
2274	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
2275	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
2276	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
2277	Idarubicin HCl for injection	Idamycin	2/12/1991	Treatment of acute lymphoblastic leukemia in pediatric patients.	Pharmacia & Upjohn
2278	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
2279	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2280	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
2281	Ricin (blocked) conjugated murine MCA (n901)	n/a	1/25/1991	Treatment of small cell lung cancer	ImmunoGen, Inc.
2282	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
2283	Ricin (blocked) conjugated murine mca (anti-b4)	n/a	1/24/1991	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc.
2284	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
2285	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
2286	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
2287	Cladribine	Leustatin Injection	12/31/1990	Treatment of chronic lymphocytic leukemia.	Janssen Research & Development, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2288	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
2289	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
2290	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
2291	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
2292	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
2293	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm ³).	Amgen, Inc.
2294	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
2295	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
2296	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
2297	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2298	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
2299	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
2300	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
2301	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
2302	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.
2303	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
2304	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
2305	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
2306	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2307	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
2308	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
2309	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
2310	Cladribine	Leustatin	7/20/1990	Treatment of acute myeloid leukemia.	Janssen Research & Development, LLC
2311	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
2312	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
2313	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
2314	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
2315	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2316	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
2317	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
2318	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
2319	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
2320	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
2321	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Medimmune LLC
2322	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Medimmune, LLC

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2323	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
2324	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
2325	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
2326	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
2327	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
2328	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
2329	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2330	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
2331	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
2332	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
2333	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.
2334	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
2335	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
2336	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
2337	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
2338	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2339	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
2340	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
2341	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
2342	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
2343	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
2344	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	2/1/1990	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc.
2345	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
2346	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer, Inc.
2347	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2348	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
2349	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma	Guilford Pharmaceuticals, Inc.
2350	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2351	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
2352	Corticotropin ovine triflutate	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc.
2353	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
2354	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
2355	Levocarnitine	Carnitor	11/15/1989	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
2356	Levocarnitine	Carnitor	11/15/1989	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2357	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
2358	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
2359	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
2360	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Sigma-tau Pharmaceuticals, Inc.
2361	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc.
2362	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc.
2363	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
2364	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2365	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
2366	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2367	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
2368	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
2369	Ricin (blocked) conjugated murine MCA (anti-my9)	n/a	8/3/1989	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc.
2370	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
2371	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
2372	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
2373	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2374	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
2375	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
2376	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
2377	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
2378	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
2379	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.
2380	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
2381	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2382	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
2383	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
2384	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
2385	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
2386	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
2387	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services
2388	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
2389	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
2390	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2391	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
2392	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
2393	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
2394	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
2395	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
2396	Ricin (blocked) conjugated murine MCA (anti-B4)	n/a	11/17/1988	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc.
2397	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
2398	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
2399	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
2400	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
2401	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2402	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
2403	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Vidara Therapeutics Research Limited
2404	Sotalol HCl	Betapace	9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc.
2405	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
2406	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
2407	Thalidomide	n/a	9/19/1988	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
2408	Thalidomide	n/a	9/19/1988	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
2409	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
2410	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2411	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2412	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
2413	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
2414	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
2415	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
2416	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
2417	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
2418	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
2419	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
2420	Polyribonucleotide; Polyribonucleosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
2421	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2422	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
2423	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
2424	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
2425	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
2426	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (\geq 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute
2427	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2428	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.
2429	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
2430	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
2431	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
2432	Pentamidine isethionate	Nebuvent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
2433	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
2434	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2435	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
2436	Dextran sulfate sodium	n/a	11/19/1987	Treatment of acquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
2437	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
2438	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
2439	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
2440	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
2441	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
2442	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2443	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
2444	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administering penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC
2445	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
2446	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
2447	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
2448	Acetylcysteine	Mucomyst/Mucomyst 10 lv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
2449	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2450	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
2451	Mefloquine HCl	Mephaquin	7/22/1987	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG
2452	Mefloquine HCl	Mephaquin	7/22/1987	Treatment of chloroquine-resistant Falciparum malaria.	Mepha AG
2453	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
2454	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals
2455	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
2456	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
2457	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2458	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
2459	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
2460	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
2461	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2462	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
2463	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
2464	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2465	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2466	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
2467	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
2468	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
2469	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
2470	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
2471	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
2472	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
2473	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2474	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
2475	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
2476	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
2477	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
2478	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
2479	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
2480	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
2481	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
2482	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
2483	Beractant	Survanta Intratracheal Suspension	2/5/1986	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2484	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories
2485	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	Immunex/Immunex
2486	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
2487	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
2488	Antithrombin III human	Antithrombin Iii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2489	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
2490	Somatrem for injection	Protropin	12/9/1985	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2491	Somatrem for injection	Protropin	12/9/1985	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
2492	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
2493	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
2494	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
2495	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
2496	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
2497	Pentastarch	Pentaspán	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals
2498	Ifosfamide	Ifex	8/7/1985	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2499	Ifosfamide	Ifex	8/7/1985	Treatment of bone sarcomas	Bristol-Myers Squibb Company
2500	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
2501	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
2502	Zidovudine	Retrovir	7/17/1985	Treatment of AIDS related complex.	Glaxo Wellcome Inc.
2503	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
2504	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
2505	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. (Roberts Pharmaceutical Corp.)
2506	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
2507	Surface active extract of saline lavage of bovine lungs	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
2508	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
2509	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2510	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals
2511	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
2512	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
2513	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2514	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
2515	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
2516	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
2517	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
2518	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
2519	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
2520	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation

**Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014**

2521	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
2522	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
2523	Potassium citrate	Urocit-K	11/1/1984	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas
2524	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
2525	Potassium citrate	Urocit-K	11/1/1984	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
2526	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
2527	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
2528	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2529	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
2530	Chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.	Solvay
2531	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
2532	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
2533	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
2534	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
2535	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2536	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
2537	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
2538	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
2539	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
2540	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphryria.	Abbott Laboratories
2541	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
2542	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
2543	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
2544	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 12-02-2013
Governs January 1, 2014 - March 31, 2014

2545	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
------	-------------	---------	----------	--	--------------------------